Shares of Aurobindo Pharma Ltd have been buying and selling virtually 2% decrease on Tuesday, 26 August, regardless of its subsidiary gaining regulatory approval in the UK to market its most cancers remedy medication.
CuraTeQ Biologics s.r.o., Aurobindo Pharma’s wholly-owned step-down subsidiary, has obtained advertising and marketing authorisation from the UK’s Medicines and Healthcare Merchandise Regulatory Company (MHRA) to market Dazublys, a trastuzumab biosimilar model, based on a submitting.
The current improvement comes after Dazublys obtained clearance from the European Fee (EC) for the European Union market in July 2025.
Dazublys is a drug used to deal with HER2-positive breast and gastric most cancers. The medication impacts the HER2 protein, which promotes tumour development.
CuraTeQ’s clearance is the fourth biosimilar to obtain MHRA approval, following Bevqolva in December 2024, Zefylt in Could 2025, and Dyrupeg in June 2025. Dazublys, Zefylti, and Dyrupeg have additionally obtained permission within the bigger European Union market, based on the enterprise.
Santhanam Subramanian, Chief Monetary Officer (CFO) of Aurobindo Pharma, confirmed in an unique interview on 21 August that the corporate has entered right into a Non-Disclosure and Confidentiality settlement for its potential acquisition of Zentiva, and that talks are at present at a “very early stage.”
In accordance with Subramanian, Zentiva’s involvement in Aurobindo Pharma’s strategic objective is smart given Zentiva’s European foundation; nonetheless, any concrete pronouncements on the potential end result are untimely because of the early stage of negotiations. If a deal is reached, Subramanian thinks that an announcement shall be made inside the subsequent two months.
Aurobindo Pharma at present has $140 million in property and generates 75% of its revenue from the US and European markets, bolstering its glorious monetary place.
Subramanian emphasised that, whereas inspecting massive corporations for acquisitions is just not essentially incorrect, the corporate will train diligence to stop overpayment in any potential transaction. He additionally said that Aurobindo Pharma would like to comply with offers involving single-digit multiples.
At 1:15 pm, the shares of Aurobindo Pharma have been buying and selling 1.79% decrease at Rs 1,048.30 on NSE.
Feeling overwhelmed by the markets? Let Unicorn Indicators be your information. Our user-friendly app simplifies advanced information and supplies actionable buying and selling alerts. Obtain the app in the present day and commerce with confidence!
